Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

GAITHERSBURG, Md., Aug.  06, 2020  (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter 2020 financial and operating results following the close of U.S. financial markets on Monday, August 10, 2020.

Novavax to Host Conference Call to Discuss Second Quarter Financial and Operating Results on August 10, 2020

Novavax, Inc (NASDAQ: NVAX) disclosed Wednesday it had entered into an agreement with the Serum Institute of India Private Limited for development, distribution, and commercialization of its COVID-19 vaccine in several countries.

Novavax Inks Deal With India's Serum Institute To Make Coronavirus Vaccine Available In Low, Middle Income Countries

Novavax, Inc. (NASDAQ: NVAX) announced positive results from the Phase 1 portion of the Phase 1/2 trial of its coronavirus vaccine candidate, and it appears best-in-class, JPMorgan said in a Wednesday upgrade.

JPMorgan Turns Bullish On Novavax After Phase 1 Coronavirus Vaccine Readout

Novavax Inc. (NASDAQ: NVAX) shares hit another all-time high on Wednesday after the company announced positive results from its early stage COVID-19 vaccine study.

Novavax Bulls Keep Charging as More COVID-19 Results Come Out

Novavax stock shot up to a record high Wednesday after the company announced some positive results from early-stage testing of a coronavirus vaccine that has $1.6 billion in U.S. funding.
The post Novavax Stock Spirals To Record High On Positive Coronavirus Vaccine Data appeared first on Investor's Business Daily.

Novavax Stock Spirals To Record High On Positive Coronavirus Vaccine Data

Novavax's COVID-19 vaccine might be the best of the bunch.

Why Novavax Stock Is Printing a New All-Time High Today

NVAX stock is one of the hottest biotech stocks in 2020. But it's time for the company to deliver results worthy of its price.

Novavax Stock Needs Solid Results Beyond Headlines

The market went crazy after reports emerged about the safety of Novavax's Covid-19 vaccine. Here's what you need to know about NVAX stock.

How to Approach Novavax Stock After Tuesday’s 35% Swing

A $1.6 billion government award pushed the shares higher.

Why Novavax Soared 71.7% in July

Novavax, Inc (NASDAQ: VAX) announced Tuesday its novel coronavirus (COVID-19) vaccine elicited "robust antibody responses" in participants of the Phase 1 clinical trial.

Novavax Says Coronavirus Vaccine Generated 'Robust Antibody Responses' In Phase 1 Trial Participants

Whether the vaccine protects against COVID-19 remains to be seen.

Novavax's Coronavirus Vaccine Induced Antibodies in 100% of Phase 1 Trial Participants

The Maryland-based biotech company received a $1.6 billion deal from the federal government for its experimental coronavirus vaccine.

Novavax Stocks Jumps 8.5% After ‘Positive’ Early Results For Its Coronavirus Vaccine

Novavax's potential vaccine to prevent Covid-19 generated a promising immune response in an early-stage clinical trial, the U.S.-based biotech firm announced Tuesday.

Novavax's coronavirus vaccine generates promising immune response in early trial, data shows

GAITHERSBURG, Md., Aug.  04, 2020  (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced Phase 1 data from its Phase 1/2 randomized, observer-blinded, placebo-controlled trial of its COVID‑19 vaccine with and without Matrix‑M™ adjuvant in healthy adults 18-59 years of age. NVX‑CoV2373, the Company’s recombinant COVID-19 vaccine candidate adjuvanted with Matrix-M, was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera. The data have been submitted for peer-review to a scientific journal and to an online preprint server at medRxiv.org.

Novavax Announces Positive Phase 1 Data for its COVID-19 Vaccine Candidate

AstraZeneca

BioNTech SE

GlaxoSmithKline

Inovio Pharmaceuticals

Johnson & Johnson

Moderna

Pfizer

MRNA, PFE/BNTX, and AZN are leading the three vaccines in clinical phase 3 trials.

Phase 3 Trials And More: Any COVID-19 Data Is Good Data, Even If It's Bad

QuidelOrtho Corp

Two very different companies with two very promising COVID-19 programs.

Better Coronavirus Stock: Novavax vs. Quidel

The shares have soared as vaccine candidates progress through human trials. Can the gains continue?

Should You Sell These Coronavirus Vaccine Stocks?

Sanofi

These Coronavirus Vaccine Makers Are Winning the Money Game So Far

The coronavirus pandemic has been good news for investors in pharma companies racing to develop a Covid-19 vaccine. Stock prices for many of the competing companies are trading around record highs.

Are Covid Vaccine Stocks Worth Investing In?

Novavax (NASDAQ:NVAX) looks on its way to a credible vaccine. If so, NVAX stock going to $200 by  the end of the years seems all but certain.

Novavax at $200 a Pop by the End of 2020 Seems Like an Easy Target

Range Resources

Unisys

These are the small cap stocks with the best value, fastest growth, and most momentum for August.

Top Small Cap Stocks for August 2020

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Novavax (NVAX) Report Negative Q2 Earnings? What You Should Know

Novavax has been one of the companies cashing in on the race to find a vaccine against COVID-19. As a result NVAX stock is up over 3,000% year-to-date
The post As Optimism Wanes, the Ride May Be Over for Novavax stock appeared first on InvestorPlace.

As Optimism Wanes, the Ride May Be Over for Novavax stock

Catalent

Emergent BioSolutions

Lonza Group AG

The Race To Erase COVID-19

Novavax (NVAX) is developing a coronavirus vaccine. While increased clinical activity is expected to have increased expenses, pipeline development grants may have offered some respite in Q2 earnings.

News for Novavax Stock (NVAX)